Hepion pharmaceuticals to participate in the cantor oncology, hematology & hemeonc conference

Edison, n.j., sept. 26, 2022 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical stage biopharmaceutical company focused on artificial intelligence (“ai”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“nash”), hepatocellular carcinoma (“hcc”), and other chronic liver diseases, today announced that its chief medical officer, todd hobbs, md, will participate in the “novel targets in oncology: risk vs. reward” panel at the cantor oncology, hematology & hemeonc conference on wednesday, september 28, 2022 at 9:00 a.m. eastern time at the new york palace hotel.
HEPA Ratings Summary
HEPA Quant Ranking